US 12,433,917 B2
Enriched multilayer amnion derived tissue graft
Christian Beaudry, Phoenix, AZ (US); Merrill B. Stromer, Phoenix, AZ (US); and Grant D. Senner, Phoenix, AZ (US)
Assigned to Amnio Technology LLC, Phoenix, AZ (US)
Filed by Amnio Technology LLC, Phoenix, AZ (US)
Filed on Dec. 27, 2021, as Appl. No. 17/562,839.
Application 17/562,839 is a continuation of application No. 15/909,857, filed on Mar. 1, 2018, granted, now 11,207,355.
Application 15/909,857 is a continuation in part of application No. 15/542,444, granted, now 10,517,903, issued on Dec. 31, 2019, previously published as PCT/US2015/050046, filed on Sep. 14, 2015.
Application 15/542,444 is a continuation in part of application No. 14/593,415, filed on Jan. 9, 2015, granted, now 9,132,156, issued on Sep. 15, 2015.
Application 15/542,444 is a continuation in part of application No. PCT/US2015/019294, filed on Mar. 6, 2015.
Application 15/542,444 is a continuation in part of application No. PCT/US2015/019318, filed on Mar. 6, 2015.
Application 15/542,444 is a continuation in part of application No. PCT/US2015/019311, filed on Mar. 6, 2015.
Application 15/542,444 is a continuation in part of application No. PCT/US2015/035746, filed on Jun. 15, 2015.
Application 15/909,857 is a continuation in part of application No. 15/257,870, filed on Sep. 6, 2016, granted, now 10,894,066, issued on Jan. 19, 2021.
Application 15/257,870 is a continuation in part of application No. PCT/US2015/019318, filed on Mar. 6, 2015.
Claims priority of provisional application 62/465,725, filed on Mar. 1, 2017.
Prior Publication US 2022/0118027 A1, Apr. 21, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/50 (2015.01); A61K 31/728 (2006.01); A61K 35/28 (2015.01); A61K 35/35 (2015.01); A61L 27/36 (2006.01); A61L 27/38 (2006.01)
CPC A61K 35/50 (2013.01) [A61K 31/728 (2013.01); A61K 35/28 (2013.01); A61K 35/35 (2013.01); A61L 27/3604 (2013.01); A61L 27/3683 (2013.01); A61L 27/3804 (2013.01)] 19 Claims
 
1. An enriched amnion derived tissue graft comprising:
a) a first tissue layer having a protein concentration and comprising:
i) a first amnion layer;
ii) an outside surface;
iii) a treatment surface; and
b) an enrichment composition coupled to first tissue layer to produce an enriched portion wherein the enrichment composition comprises:
i) acellular amniotic membrane particles;
ii) a carrier fluid; wherein the acellular amniotic membrane particles consist essentially of micronized amniotic membrane;
wherein the carrier comprises an acellular amniotic fluid; and
wherein the enrichment composition is essentially free of any viable amniotic membrane cells or viable amniotic fluid cells.